Taiwan Generic Pharmaceutical Market Status & Issues

Transcription

1 Taiwan Generic Pharmaceutical Market Status & Issues The 15th Annual IGPA Conference 2012 Kyoto, Japan Taiwan Generic Pharmaceutical Association Tiffany Chen

2 OUTLINE Taiwan Pharmaceutical Market Overview Major Issues Possible Solutions

3 Population: 23 million Healthcare providers: HP: 477 GP: 9,956 DS: 5,199 (contracted) Geography Generic definition follows IMS Taiwan definition, Which consider all local manufactures are generics and foreign manufactures are branded due to Taiwan IMSPlus data limitation

4 Overview 1/20 Exchange Rate : 29.5 (NT$/1 US$)

5 Overview 2/20

6 Overview 3/20

7 Overview 4/20 Foreign companies: 30 Local companies: 160

8 Overview 5/20 Medical center: 22 Regional hospital: 83 Area hospital: 372 Total: 477

9 Overview 6/20 Total: 5,199 (Contracted)

10 Overview 7/20 Total : 9,956

11 Overview 8/20

12 Overview 9/20

13 Overview 10/20

14 Overview 11/20

15 Overview 12/20

16 Overview 13/20

17 Overview 14/20

18 Overview 15/20

19 Overview 16/20

20 Overview 17/20

21 Overview 18/20

22 Overview 19/20

23 Overview 20/20

24 Major Issues Branded products still dominate Taiwan market (77% versus 23%) National Health Insurance policy still plays the key role as well as the coming 2 nd generation NHI Relatively lower medical expenditure versus other countries Reimbursement price cut led by price-volume survey (PVS) every two years Bureau of Health Insurance presents the continuing financial deficit

25 Lower Medical Expenditure Medical expenditure/gdp USA Holland France Switzerland Germany Canada Austria Belgium New Zealand Sweden England Spain Japan Norway Italy Australia Finland USA Switzerland Norway Holland Canada Austria Germany France Belgium Sweden Australia England Finland Spain Japan New Zealand Italy Czech Taiwan S. Korea S. Korea Taiwan Mexico Czech Mexico Average medical expenditure/ person/year

26 Major Issues Products losing patent protection will have their prices reduced to a reasonable level within five years, under Article 46 of the 2G NHI Act, due to be implemented at the start of As a result, there will be deeper cuts to prices earlier than before which will lower the motivation to multinational companies launching new products in Taiwan Foreign generics take the advantage of higher reimbursement price compare to local generics

27 Major Issues The BNHI is now starting its review process as soon as the Taiwan Food and Drug Administration issues an approval letter, which should save three or more months from the time taken for reimbursement listing and pricing. However, the drug lag in Taiwan will get even longer if China starts to benchmark low Taiwanese prices, since companies will want to be approved first in the larger market before launching in Taiwan

28 Possible Solution Generic penetration will accelerate, helped by higher prices up to 100% of the original product price - for generics that meet tougher quality standards, as manufacturers will be able to answer quality concerns and offer larger discounts

29 Possible Solution The introduction of the second-generation National Health Insurance (2G NHI) Act in 2013 will boost the finances of the NHI system through the introduction of supplementary premiums. However, there are fears that this may not raise enough to ensure the NHI s financial stability for the next five years, and the Bureau of National Health Insurance (BNHI) may try to minimize the promised cut in basic premium rates.

30 Possible Solution Total healthcare expenditure accounted for 6.8% of GDP in The government intends to increase spending on healthcare to 7.5%. Healthcare policy will seek to address the challenges of the ageing population and the rise in chronic disease. The Department of Health (DOH) has started work on a long-term care system for the elderly and disabled and is putting more resources into preventative care

31 Possible Solution By the end of 2014, all domestic manufacturers will have to meet Pharmaceutical Inspection Convention/Co-operation Scheme good manufacturing practice (PIC/S-GMP) standards, which will lead to some companies leaving the market and a rise in contract manufacturing The local industry is expected to consolidate and concentrate, with the leading companies using the higher prices for improved manufacturing standards to increase their market share

32 Thanks For Your Attention! Reference: Taiwan DOH IMS